"Amid all the warnings about a ‘dementia tsunami’, here are the things you should know. When we dig into new research we see why all the alarming headlines are written, but also that science is bringing new hope." 🧪🧠 #neuroskyence www.theguardian.com/commentisfre...

Amid all the warnings about a ‘dementia tsunami’, here are the things you should know | Devi Sridhar

When we dig into new research we see why all the alarming headlines are written, but also that science is bringing new hope, says Devi Sridhar, chair of global public health at the University of Edinb...

theguardian.com

God, it's brutal out here

No better way to kick off this next chapter than spending my first full day in Boston—after 8 years in California—at the MassBio conference. Grateful for the warm welcome and excited for what’s ahead.

Interleukin-12 signaling drives Alzheimer’s disease pathology through disrupting neuronal and oligodendrocyte homeostasis www.nature.com/articles/s43...

Interleukin-12 signaling drives Alzheimer’s disease pathology through disrupting neuronal and oligodendrocyte homeostasis - Nature Aging

Schneeberger, Kim, Geesdorf, Rajewsky, Heppner et al. tease IL-12 and IL-23 signaling apart in mouse models and human brain tissue to define a role for oligodendroglial and neuronal IL-12 signaling in...

nature.com

Regardless of how unfair it is that these projects receive funding while therapeutics do not, these mice are ridiculously cute

WIRED@wired.com · last yr.

The de-extinction company Colossal Biosciences wants to bring back the mammoth, and it’s starting with a woolly mouse. Read more here: buff.ly/xKPLn1c

Watching Severance and interpreting it as a TV show about an intricate clinical trial design makes it even more mind-blowing

Governments should aim to become leaner—when it’s feasible to do more with less. But shedding weight at record speed by cutting off both arms and legs isn’t exactly a winning long-term strategy

Feels like Christmas morning—can’t wait to read this one! @charlespiller.bsky.social

Why limit yourself to developing neurodegenerative therapies when you can also create art? With a cofounder who’s both a scientist and an artist, the possibilities are endless 👨🏻‍🔬👨🏻‍🎨

Excited to share that I'll be attending the Global Healthspan Summit 2025 as Momentum Therapeutics continues advancing our mission to develop novel therapies that protect the nervous system and combat aging. If you'll be there, let’s connect! #Hevolution #Healthspan #GHS2025

We knew about the potential origin of Parkinson's disease from the gut (known as Braak’s hypothesis). But the kidney?! www.nature.com/articles/s41...

Propagation of pathologic α-synuclein from kidney to brain may contribute to Parkinson’s disease - Nature Neuroscience

Yuan et al. find that the kidney can serve as a site of initiation for the spread of pathological α-synuclein to the brain, contributing to the development of Parkinson’s disease (PD) and providing a ...

nature.com

This is the mantra. Insitro’s CEO Daphne Koller for Endpoints:

A neurologist with 2 APOE4 copies tells us about his experience with #Alzheimers disease washingtonpost.com/wellness/202...

Argentina is the only country in South America with Nobel Prizes in scientific categories, and has made significant contributions to global science, particularly in biochemistry and medicine.

Mike Fainzilber@mfainzilber.bsky.social · 2y ago

The decimation of science in Argentina www.nature.com/articles/d41...

it's big, and it's a review of 601 papers on the topic - but here's an update on Neuroinflammation in Alzheimer's Disease www.nature.com/articles/s41... led by Michael Heneka, published in @natrevimmunol.bsky.social today (MANY more authors listed and linked below)

Neuroinflammation in Alzheimer disease - Nature Reviews Immunology

This Review provides an in-depth examination of how inflammation contributes to neurodegeneration in Alzheimer disease. The authors explore the impact of extrinsic factors, such as brain trauma, diet ...

nature.com

Brain delivery has the potential to transform patient care - and it could become a reality soon. This snapshot of transcytosis strategies (from GS) highlights how neurobiotech is on the verge of revolutionizing treatments for CNS diseases. I only wish Montara had been included in the discussion.

A sincere and shameless plug: This Thanksgiving, I’m especially grateful for my healthy axons. Photo Credit: Felipe Court, our Chief Scientific Officer.

My advice to graduates of my class who still (!) insist on going into #biotech investment banking First, a few tips re science/medical data:

Neuroscience and obesity continue to stand out as the dominant and perhaps only major headwinds driving biopharma business development this year, consistently delivering impressive deals and partnerships.

Kyle LaHucik@kylelahucik.bsky.social · 2y ago

Novartis acquires Astellas-partnered Kate Therapeutics, a neuromuscular gene therapy startup, for up to $1.1 billion Follows MorphoSys, Mariana acquisitions earlier this years, with more hunger for additional bolt-on deals

Made a biotech founders starter pack, DM me to be added! go.bsky.app/LWm8uPE

Who’s building a neuroscience and a biotech founder “starter packs”? #biosky #medsky

Proud to be part of this movement alongside brilliant peers and friends shaping the future of innovation in biotech.

C&EN (Chemical & Engineering News)@cenmag.bsky.social · 2y ago

Cashing in on founder-led biotech Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite cen.acs.org/business/sta... #chemsky

First post here! Excited to connect, learn, and join meaningful conversations. #BioSky #SciSky